Immunology Market

Market Definition

Immunology market size is valued at USD 99.1 billion in 2025 and is projected to reach USD 215.6 billion in 2033, at a CAGR of 10.2% from 2026 to 2033

Immunology is a study of immune system that protects the body from infection through various lines of defence. The dysfunction in the immune system can cause immunological disorders including allergy, autoimmune diseases, asthma, autoinflammatory syndromes and cancer. The immunological disorders can be treated form monoclonal antibody (mAb), immunosuppressants, polyclonal antibody (pAb), fusion proteins, and others.

Market Dynamics

Rising prevalence of autoimmune and other immunological disorders are key driving factors of the market. Immunological disorders are caused by a dysfunction of the immune system including allergy, autoimmune diseases, asthma, autoinflammatory syndromes and immunological deficiency syndromes. According to the National Institutes of Health (NIH), globally, more than 700 million people, nearly one-tenth of the global population suffer from autoimmune disease. According to the American Autoimmune Related Diseases Association (AARDA), up to 50 million Americans suffer from an autoimmune disease and the prevalence is expected to rise in the coming years. According to the British Society for Immunology, more than four million people in the UK have an autoimmune condition. However, the side effect of immunotherapy might hamper market growth. The most common side effect of immunotherapy includes skin redness, blistering, dryness, fever, weakness, vomiting, nausea, body aches, dizziness, and high or low blood pressure. Moreover, increasing investment for immunotherapy would provide lucrative opportunities for the market in the coming years.

Market Segmentation

The global immunology market is mainly classified based on type and application. Type is further segmented into Monoclonal Antibodies (mAb), Immunosuppressants, Polyclonal Antibody (pAb), Fusion Proteins, and Others. By application, the market is divided into Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Prophylaxis of Organ Rejection, Inflammatory Bowel Disease, and Others. 

Monoclonal Antibodies(mAb) segment is valued at USD 52.2 billion in 2026 and is projected to reach USD 107.8 billion by 2033, at a CAGR of 10.9% during the forecast period. For instance, AbbVie has received the U.S. Food and Drug Administration (FDA) approval for SKYRIZI (risankizumab-rzaa). SKYRIZI is an interleukin-23 (IL-23) inhibitor for the treatment of moderate to severe plaque psoriasis in adults.

By Application, Rheumatoid Arthritis segment is projected to reach USD 81.9 billion by 2033, at a CAGR of 9.5% during the forecast period. 

Regional Analysis

Based on geography, the global immunology market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America was dominating the global immunology market in 2025, due to the rising incidence of autoimmune and other immunological disorders, commercialization of new immunology products, increasing clinical studies, the partnership between companies to develop and commercialize new immunology products, and government support to develop immunology products. For instance, The National Institute of Allergy and Infectious Diseases (NIAID) a part of the National Institutes of Health, has funded $30 million three institutions to provide new centers of immunology research for tuberculosis (TB) vaccine development. The three institutions include the Harvard T.H. Chan School of Public Health in Boston, the Infectious Disease Research Institute of Seattle, and the Seattle Children’s Hospital.

 

Competitive landscape

Key players operating in the immunology industry include AbbVie Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Astellas, Janssen, Novartis AG, Merck, UCB SA, Bristol-Myers Squibb, and Amgen Inc.

The increasing commercialization of immunology products, rising clinical studies on immunology products, the partnership between companies to develop and commercialize of immunology products, increasing investment and funding by the companies to develop and commercialize immunology products and increasing regulatory approval for immunology products are some of the strategies adopted by the major companies. For instance, on March 26, 2020, Bristol-Myers Squibb Company has received the U.S. Food and Drug Administration (FDA) approval for ZEPOSIA (ozanimod) 0.92 mg for the treatment of relapsing forms of multiple sclerosis (RMS) in adults. ZEPOSIA is an oral medication, is the only approved sphingosine-1-phosphate (S1P) receptor modulator.

Immunology Market Key Segments:

By Type

• Monoclonal Antibodies(mAb)
• Immunosuppressants
• Polyclonal Antibody(pAb)
• Fusion Proteins
• Others

By Application

• Rheumatoid Arthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Plaque Psoriasis
• Prophylaxis of Organ Rejection
• Inflammatory Bowel Disease
• Others

Key Global Immunology Industry Players

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• Astellas
• Janssen
• Novartis AG
• Merck
• UCB SA
• Bristol-Myers Squibb
• Amgen Inc.

Report Attributes	Details
Study Period	2021-2033
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2033
Historical Period	2021-2025
Growth Rate	CAGR 10.2% from 2026 to 2033
Revenue Unit	USD billion
Sales Volume Unit	Units
Segmentation	By Type, Application, and Region
By Region	North America (By Type, Application, and Country) United States Canada Mexico
	Europe (By Type, Application, and Country) Germany France UK Italy Spain Russia Rest of the Europe
	Asia Pacific (By Type, Application, and Country) China Japan India South Korea Australia Southeast Asia Rest of Asia Pacific
	South America (By Type, Application, and Country) Brazil Argentina Rest of South America
	Middle East and Africa (By Type, Application, and Country) Saudi Arabia UAE South Africa Rest of Middle East and Africa

What Report Provides

• Key Company Market Share, Revenue, and Position/Ranking
• Key Market Leaders
• Full In-Depth Analysis of the Parent Industry
• Industry Statistics
• Important Changes in Market and Its Dynamics
• Segmentation Details of the Market
• Historical, On-Going, and Projected Market Analysis
• Assessment of Niche Industry Developments
• Market Share Analysis
• Key Strategies of Major Players
• Company Profiles of Key Players
• Unique Selling Prepositions of Leading Market Players
• Emerging Segments and Regional Growth Potential
• Key Strategic Recommendations
• Competitive Benchmarking
• Import Export Trade Statistics